PubRank

Giulia Taraboletti

Author PubWeight™ 20.12‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 2003 2.14
2 Cathepsin B mediates the pH-dependent proinvasive activity of tumor-shed microvesicles. Neoplasia 2008 1.19
3 Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. Blood 2003 1.07
4 Reduced expression of the ROCK inhibitor Rnd3 is associated with increased invasiveness and metastatic potential in mesenchymal tumor cells. PLoS One 2010 1.01
5 Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion. Mol Cancer Res 2008 0.99
6 Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain. Int J Biochem Cell Biol 2007 0.95
7 Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res 2003 0.95
8 Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds. J Biol Chem 2010 0.94
9 Gorham-Stout syndrome: a monocyte-mediated cytokine propelled disease. J Bone Miner Res 2005 0.93
10 The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts. Mol Cancer Ther 2012 0.92
11 Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. Eur J Cancer 2006 0.92
12 Vascular disrupting activity of tubulin-binding 1,5-diaryl-1H-imidazoles. J Med Chem 2009 0.90
13 ERK1-2 and p38 MAPK regulate MMP/TIMP balance and function in response to thrombospondin-1 fragments in the microvascular endothelium. Life Sci 2004 0.85
14 Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1. Int J Cancer 2014 0.84
15 Targeting angiogenesis with compounds from the extracellular matrix. Int J Biochem Cell Biol 2011 0.84
16 Tumor-host interaction in the optimization of paclitaxel-based combination therapies with vascular targeting compounds. Cancer Metastasis Rev 2007 0.83
17 Direct and allosteric inhibition of the FGF2/HSPGs/FGFR1 ternary complex formation by an antiangiogenic, thrombospondin-1-mimic small molecule. PLoS One 2012 0.82
18 Inhibition of SIRT2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapies. Neoplasia 2012 0.82
19 Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. Cancer Chemother Pharmacol 2013 0.79
20 Thrombospondin-1 is part of a Slug-independent motility and metastatic program in cutaneous melanoma, in association with VEGFR-1 and FGF-2. Pigment Cell Melanoma Res 2014 0.79
21 Hepatocyte growth factor (HGF) downregulates thrombospondin 1 (TSP-1) expression in thyroid papillary carcinoma cells. J Pathol 2005 0.78
22 45th annual meeting of the Italian Cancer Society. Bergamo, 9-12 November 2003. Tumori 2004 0.75